Merck & Co. and Schering-Plough agreed to pay $41.5 million to resolve claims related to cholesterol drugs Vytorin and Zetia. Class-action lawsuits were filed over the cost of the pills after they were found in a clinical trial to be as effective as a cheaper treatment in reducing plaque in carotid arteries.

Full Story:

Related Summaries